Loading
A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma is a phase 1/2 interventional study registered as NCT02773030 by Celgene, with 466 participants enrolled, started 2016-10-14 and due to reach its primary completion in 2024-05-09. Interventions recorded: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
466 enrolled.
95% CI 18.1 to 35.6; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication · 95% CI 0.5 to 71.6
Sourcerange 0.1 to 395.0; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication · range 0.1 to 247.0 · range 0.1 to 150.1 · range 2.1 to 269.1 · range 0.1 to 258.1 · range 4.1 to 246.3 · range 5.3 to 213.1 · range 8.3 to 46.7 · range 0.1 to 84.4 · range 0.1 to 127.9 · range 0.1 to 81.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) in Cohort D and Cohort H2primary | Cohort D: Treatment 1 | 107 | 26.2% | - | - | link |
| Cohort H2 | 5 | 20% | ||||
| Progression Free Survival | Cohort A: Total | 29 | 12.29 weeks | - | - | link |
| Cohort B: Total | 90 | 14.71 weeks | ||||
| Cohort D: Total | 107 | 12.14 weeks | ||||
| Cohort E: Total | 50 | 20.71 weeks | ||||
| Cohort F: Total | 29 | 15.14 weeks | ||||
| Cohort G: Total | 16 | 48.57 weeks | ||||
| Cohort H1 | 6 | 26.14 weeks | ||||
| Cohort H2 | 5 | 22.14 weeks | ||||
| Cohort I | 41 | 10.14 weeks | ||||
| Cohort J: Total | 18 | 107 weeks | ||||
| Cohort K | 75 | 57.14 weeks |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Daratumumab, Bortezomib.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Bortezomib, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Carfilzomib, Daratumumab, Bortezomib, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/